
Remix Therapeutics
Reprogramming RNA to transform patients' lives.
Series B+ ·
Amount not disclosed in a source on record.
Funding history ↓Signals
Website registeredJul 2, 2019 (7 years old)
Funding rounds
| Date | Round | Amount | Lead | Source |
|---|---|---|---|---|
| Series B+ | undisclosed | — | fundraisingfox.com |
Timeline
- Website created
Founders and team
- PSPeter Smith Co-Founder, President and Chief Executive Officersource: remixtx.com
Acquisitions
| Acquired company | Price | Announced |
|---|---|---|
| Not disclosed publicly |
Similar Health and bio companies
VVumedi$140M Series B+ · Nov 2026
NNeurosterix$105M Series B+ · Nov 2026
OOSMUNDA$14.99M Series B+ · Nov 2026
BBoston Medical Sciences$34.69M Series B+ · Nov 2026
AAraceli Biosciences$4.5M Seed · Nov 2026
PPhrontline Biopharma$40M Series A · Nov 2026
Sources and API
Every amount links to the page it came from. * Estimated from an accelerator's published standard deal, not a company-specific disclosure. How Recent Funding sources and verifies funding data. The same data as JSON: /api/v1/companies/remix-therapeutics (get a free API key).